ArticleBMC pulmonary medicine2023
Diagnostic value of a nanopore sequencing assay of bronchoalveolar lavage fluid in pulmonary tuberculosis.
Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of nanopore sequencing for detecting Mycobacterium tuberculosis and drug-resistant strains: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Diagnostic Performance of Nanopore-targeted Sequencing for Sputum Smear-negative Pulmonary Tuberculosis: A Retrospective Study.Open forum infectious diseases · 2026Article
- The diagnostic value of Xpert detection combined with nanopore sequencing for tuberculosis in HIV/AIDS patients.Infectious medicine · 2026Article
- Targeted sputum sequencing for rapid and broad drug resistance of Mycobacterium tuberculosis.Infection · 2025Article
- Study on the early diagnostic value of nanopore sequencing in alveolar lavage fluid smear-negative pulmonary tuberculosis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Article
- The diagnostic value of third-generation nanopore sequencing in non-tuberculous mycobacterial infections.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Diagnostic Utility of Nanopore Sequencing for Tuberculous Serous Effusions.Infection and drug resistance · 2025Article
- Enhanced diagnosis of pulmonary tuberculosis through nucleotide MALDI-TOF MS analysis of BALF: a retrospective clinical study.Scientific reports · 2024Article
- Nanopore sequencing for smear-negative pulmonary tuberculosis-a multicentre prospective study in China.Annals of clinical microbiology and antimicrobials · 2024Article
- The positivity rates and drug resistance patterns ofFrontiers in public health · 2024Article
- Early assessment of fungal and oomycete pathogens in greenhouse irrigation water using Oxford nanopore amplicon sequencing.PloS one · 2024Article
- Article
- Nanopore-based targeted next-generation sequencing of tissue samples for tuberculosis diagnosis.Frontiers in microbiology · 2024Article
- Diagnostic value of nanopore sequencing technology in nontuberculous mycobacterial pulmonary disease.American journal of translational research · 2024Article
- Evaluation of Nanopore Sequencing for Diagnosing Pulmonary Tuberculosis Using Negative Smear Clinical Specimens.Infection and drug resistance · 2024Article
- Accuracy of Nanopore Sequencing as a Diagnostic Assay for Pulmonary Tuberculosis versus Smear, Culture and Xpert MTB/RIF: A Head-to-Head Comparison.Tropical medicine and infectious disease · 2023Article
- Pathogen spectrum identified by targeted nanopore sequencing and exploratory analysis of hematological biomarkers in suspected intracranial infections.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo determine the diagnostic accuracy of a nanopore sequencing assay of PCR products from a M. tuberculosis complex-specific region for testing of bronchoalveolar lavage fluid (BALF) samples or sputum samples from suspected pulmonary tuberculosis (PTB) patients and compare the results to results obtained for MGIT and Xpert assays.
methodsCases with suspected PTB (n = 55) were diagnosed from January 2019 to December 2021 based on results of nanopore sequencing, MGIT culture, and Xpert MTB/RIF testing of BALF and sputum samples collected during hospitalization. Diagnostic accuracies of assays were compared.
resultsUltimately, data from 29 PTB patients and 26 non-PTB cases were analyzed. PTB diagnostic sensitivities of MGIT, Xpert MTB/RIF, and nanopore sequencing assays were 48.28%, 41.38%, and 75.86%, respectively, thus demonstrating that nanopore sequencing provided greater sensitivity than was provided by MGIT culture and Xpert assays (P < 0.05). PTB diagnostic specificities of the respective assays were 65.38%, 100%, and 80.77%, which corresponded with kappa coefficient (κ) values of 0.14, 0.40, and 0.56, respectively. These results indicate that nanopore sequencing provided superior overall performance as compared to Xpert and MGIT culture assays and provided significantly greater PTB diagnostic accuracy than Xpert and sensitivity comparable to that of the MGIT culture assay.
conclusionOur findings suggest that improved detection of PTB in suspected cases was achieved using nanopore sequencing-based testing of BALF or sputum samples than was achieved using Xpert and MGIT culture-based assays, and nanopore sequencing results alone cannot be used to rule out PTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.